GlassScriptPhysician profile
Aya Pauley
NPI 1477502888
$2,726.77
in general payments reported to CMS, 2019-2025
24 companies · $903 in 2025
The $903 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $136 · 2023: $738 · 2024: $579 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.01 |
| Education | $199.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $502.32 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $471.39 | 2021-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $321.22 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $262.01 | 2022-2025 | Jynarque, Voyxact |
| Baxter Healthcare | $154.10 | 2023-2024 | Renal - Pd |
| Opko Pharmaceuticals, LLC | $121.96 | 2023-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $119.59 | 2023-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $114.88 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.49 | 2023-2025 | |
| Amgen INC. | $96.35 | 2022-2025 | Tavneos, Krystexxa |
| Vantive US Healthcare LLC | $84.17 | 2025 | Renal - Pd |
| Vifor Pharma, INC. | $57.03 | 2021 | |
| Aurinia Pharma U.S., INC. | $45.24 | 2021-2023 | Lupkynis |
| Genzyme Corporation | $40.41 | 2023-2024 | |
| Novo Nordisk INC | $38.54 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.80 | 2024 | Jardiance |
| Kyowa Kirin, INC. | $27.08 | 2023 | Crysvita |
| Ardelyx, INC. | $25.82 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $24.37 | 2021 | |
| Travere Therapeutics, INC. | $21.17 | 2024 | |
| Shield Therapeutics INC | $20.50 | 2024 | |
| Renalytix Ai, INC. | $18.41 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $15.83 | 2025 | Empaveli |
| Lilly USA, LLC | $15.09 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aya Pauley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.